Dr. Alex Spira quoted in announcement from Mirati Theraputics: Progress Of Lead Programs And Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
Virginia Cancer Specialists first patient successfully completes Cycle 1 of Treatment with PCM-075 combination with Low Dose Cytarabine (LDAC) AML Trial